Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasiroxum
Deferasirox
Brand Names
Sandoz Deferasirox (type J)
Teva-deferasirox (type J)
Exjade
Deferasirox Accord
Deferasirox Mylan
Jadenu
PMS-deferasirox
Teva-deferasirox
Apo-deferasirox
Deferasirox
Deferasirox oral
PMS-deferasirox (type J)
Auro-deferasirox (type J)
Taro-deferasirox
Deferasirox Oral Granules
Deferasorox
Deferasirox (type J)
Taro-deferasirox (type J)
Apo-deferasirox (type J)
Sandoz Deferasirox
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682